GRI 8-K SEC Filing Analysis

Latest settled — T+5d

GRI ▲ +2.33% at T+5d

NEUTRAL call ✓ call won +2.33% · α vs SPY +3.04% · entry $2.15 → $2.20

Next anchor: T+20d due 3d ago

Last close $2.25 (close Jun 12) · +4.65% from $2.15 entry

Entry anchored
May 13, 01:37 PM ET
via Databento tick

T+1d

-5.58%

call -5.58% · α -4.35%

$2.03

settled 4w ago

T+5d

+2.33%

call +2.33% · α +3.04%

$2.20

settled 25d ago

T+20d

—

call — · α —

—

due 3d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

GRI Bio reported Q1 2026 financial results with a net loss of $2.0M (improved from $3.0M in Q1 2025) and cash of $11.0M, sufficient into Q2 2027. The filing also highlighted new Phase 2a data for GRI-0621 in IPF showing zero cough, reduced dyspnea, and 61% less diarrhea versus placebo, suggesting potential to mitigate nintedanib-related GI toxicities. The company raised $6.8M via its ATM facility in Q1 2026.

Actionable Insight

The Phase 2a data is encouraging but the stock is a micro-cap ($3M market cap) with no revenue and high dilution risk. The EPS beat is a mechanical artifact of a tiny base. Watch for next financing event (cash only lasts into Q2 2027) and any partnership or regulatory update for GRI-0621.

Key Facts

Net loss of $2.0M for Q1 2026 vs $3.0M in Q1 2025
Cash and cash equivalents of $11.0M as of March 31, 2026, up from $8.2M at Dec 31, 2025
Cash runway into Q2 2027
Phase 2a data for GRI-0621 in IPF showed zero cough, 76% reduction in dyspnea, 61% less diarrhea vs placebo
Raised $6.8M in gross proceeds from ATM facility in Q1 2026
R&D expenses fell to $0.4M from $1.6M YoY due to completion of Phase 2a trial
EPS of -$1.61 vs consensus of -$3.74 (57% beat) but on a tiny base
No revenue reported (pre-revenue clinical-stage biotech)

Financial Impact

Net loss improved $1.0M YoY; cash position increased $2.8M QoQ; $6.8M ATM raise completed

cashnet lossR&D expense

Risk Factors

Nasdaq listing compliance risk (micro-cap with $3M market cap)
Dilution from ATM facility and future capital raises
Phase 2a data may not replicate in larger pivotal trials
No revenue and high cash burn rate relative to market cap
Forward-looking statements note substantial capital needed for Phase 2b trial

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

83% bullish (6 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001824293-26-000046
Exhibit: ex991_pressreleaseq126earn.htm	0001824293-26-000046
Document: 0001824293-26-000046-index-headers.html	0001824293-26-000046
Document: 0001824293-26-000046-index.html	0001824293-26-000046
Document: 0001824293-26-000046.txt	0001824293-26-000046
8-K Data (Synthetic)	0001824293-26-000046

US Market Status

Market Closed — Opens in 5h 8m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access